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A B S T R A C TObjectives: To assess patients’ preferences for rheumatoid-arthritis
treatments with biologic agents using a discrete-choice experiment.
Methods: A discrete-choice experiment was conducted with adult
rheumatoid-arthritis patients who had never been treated with
biological agents from two university hospitals—public and
private—in Buenos Aires, Argentina. We evaluated preferences for
seven treatment attributes (with two to three levels each): effective-
ness, mode of administration, frequency of administration, local and
systemic adverse events, severe infections, and out-of-pocket costs.
A probit regression model was used to analyze the relative importance
of rheumatoid-arthritis treatment attributes. We estimated attributes’
relative importance and their 95% confidence intervals. Results: Sur-
vey responses from 240 patients with rheumatoid arthritis receiving
conventional disease-modifying antirheumatic drugs were included
in the study. All tested biological agents’ attributes significantlysee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.11.007
vski@iecs.org.ar.
ondence to: Federico Augustovski, Ravignani 2024,affected the choice of treatment. Attributes’ relative importance in
decreasing order was the following (mean, confidence interval 95%):
cost, 0.81 (0.69–0.92); systemic adverse events, 0.66 (0.57–0.76); fre-
quency of administration, 0.61 (0.52–0.71); efficacy, 0.42 (0.32–0.51);
route of administration, 0.41 (0.30–0.52); local adverse events, 0.40
(0.31–0.49); and serious infections, 0.29 (0.22–0.37). Conclusions: Dif-
ferent treatment attributes had a significant and different influence in
rheumatoid-arthritis patients’ choice of biological agents. This type of
study can not only inform about patients’ preferences but also about
the trade-offs among different possible treatments or process-related
attributes.
Keywords: adverse effects, arthritis, disease-modifying antirheumatic
drugs, patient preferences, rheumatoid/drug therapy/psychology.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory
autoimmune disease and a major cause of disability [1]. Recent
studies have shown that 50% of the patients with RA are disabled
within 10 years of the onset of the disease and survival is reduced [2].
The advent of biologic agents (BAs) has had a significant
impact on the strategies followed to treat RA. While early
initiation of disease-modifying antirheumatic drugs [3] and
biologic therapy has demonstrated a prolonged benefit on RA
progression [4–6], BAs have been shown to be highly effective in
the treatment of RA [7–9]. BAs, however, have also been asso-
ciated with increased risk of toxicity and adverse events. The
combination of increased effectiveness and treatment-related
adverse events in therapies involving BAs highlights the impor-
tance of valuing the different aspects of RA treatments from a
patient’s perspective.
Information about patients’ preferences for RA treatment
attributes can be relevant in several ways. In the short run, better
understanding of patients’ preferences can help healthprofessionals improve disease management by identifying
patients’ most salient concerns [10]. Addressing patients’ con-
cerns with treatment can potentially improve adherence and
satisfaction with treatment [11]. In the long run, patients’
preferences can guide the development of future drugs to help
fulfill patients’ wants and needs. From a regulatory perspective,
understanding the relative importance of the benefits and risks
associated with RA treatments can help decision makers evaluate
therapies that provide higher/lower efficacy and risks than does
the current standard of care.
Studies in other disease areas have shown that patient and
physician priorities can differ, thereby emphasizing the need to
incorporate individual patient values into treatment decisions
[12–14]. Studies have also shown that treatment decisions among
patients with RA depend not only on personal values for
condition-related health outcomes but also on other aspects of
care such as how and where the drugs are administered, or their
cost [15,16].
Treatment decisions related to the use of BAs for RA remain
an empirical question. Choices are based on clinical severitySociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Ciudad de Buenos Aires, Buenos Aires CP 1414, Argentina
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 8 5 – 3 9 3386or disease activity, and individual patient preferences such as
concerns over adverse events, physical status, mode of adminis-
tration, and costs. Although different treatment options of BAs
are available, the effective use of BAs is limited in some countries
[17–19].
The availability of new BAs has increased the total number
of treatment options existing for this condition. Consequently,
the decision-making process in RA is now much more com-
plex. So, governments and other payers are increasingly
interested in public and patient preferences to inform decision
making to improve adherence with clinical/public health
programs.
Among different approaches to evaluate patient prefer-
ences, discrete-choice experiments (DCEs) are gaining wide
interest, because they impose relatively few assumptions and
ask respondents to choose between sets of realistic options
[20]. A main advantage of a DCE is that it can derive subjects’
preferences for different attributes of interventions in a quan-
titative way. With this approach researchers can not only
consider those treatment attributes specifically related to
health such as efficacy and safety but also those that are
process related (i.e., treatment administration at hospital or
at home, waiting time, distance). In addition, DCEs can be used
to study the expected uptake of new products and policies
[21–23] and value health outcomes for economic evaluations
[24,25].Table 1 – Attributes, definitions, and levels used for the
exercise.
Attribute Concep
n Patient Global Assessment of
disease activity (PGA)
Clinical response as a mean c
treatment. Baseline PGA: 70
Mode of administration Is the path by which a drug is
Frequency of administration Dose frequency
Local adverse events An unwanted local effect cau
Generalized adverse events An unwanted general effect c
Serious infections Any infections that might req
discontinuation of BA
Costs Monthly out-of-pocket costs o
BA, biologic agent.Incorporation of explicitly derived patient values into the
decision-making process is particularly important in the elec-
tion of BA treatment in RA: although there are minor differ-
ences in the efficacy between currently available drugs, BA
treatment options differ in other attributes such as frequency,
mode of administration, or their costs.
The main purpose of this study was to evaluate specific
preferences among biological drug attributes as well as their
relative importance among Argentinean RA patients by using a
DCE approach.
Specific objectives of the study were to 1) identify the extent
to which the attributes of a treatment (e.g., efficacy, mode of
administration, adverse events, and costs) affect patients’
choice of treatment and 2) determine the hierarchical impor-
tance of these attributes.Patients and Methods
Data Collection
Data collection was carried out in Buenos Aires, Argentina, both
at a large public teaching hospital, Instituto de Rehabilitacion
Psicofisica, and at a large private University hospital, Hospital
Italiano de Buenos Aires. The local institutional review boards of
both participating sites approved the study.construction of the discrete-choice experiment
tual definition Levels
hange from baseline before and after 1. n 40 mm
2. n 30 mm
3. n 20 mm
delivered 1. Oral
2. Subcutaneous
3. Intravenous
1. Every 10 mo
2. Every month
3. Every week
4. Every day
sed by the administration of a drug 1. No risk
2. 15 patients out of 100
3. 40 patients out of 100
aused by the administration of a drug 1. No risk
2. 10 patients out of 100
3. 30 patients out of 100
uire hospitalization for treatment and 1. 1 patient out of 100
2. 5 patients out of 100
f the hypothetical BA option 1. No out-of-pocket cost
2. $500 (Argentine pesos)
per month
3. $1500 (Argentine pesos)
per month
Fig. 1 – Example of a choice set. In its original Spanish form. Its translation in English: each row corresponds to 1. n Patient
Global Assessment of disease activity (PGA), 2. Mode of administration, 3. Frequency of administration, 4. Local adverse
events, 5. Generalized adverse events, 6. Serious infections, 7. Costs. The final one asks: Which option do you prefer?
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 8 5 – 3 9 3 387Inclusion criteria for study participants were 1) age greater
than 18 years, 2) diagnosis of RA according to the American
College of Rheumatology [26] of more than 6 months, 3) treat-
ment by a rheumatologist in an ambulatory setting, 4) taking at
least a disease-modifying antirheumatic drug, and 5) being naive
to BAs.
Patients who met the inclusion criteria and gave their consent
were interviewed by a rheumatologist to collect data related to
RA diagnosis and treatment. This included sociodemographic
data, arthritis-related health status using the validated Argentinean
Spanish version of the Health Assessment Questionnaire Dis-
ability Index [27] and disease activity assessed with the clinical
disease activity index, together with a generic health status
instrument (Euroqol EQ-5D five-dimensional questionnaire) vali-
dated in Argentina [28]. After completing the clinical assessment,
the DCE exercise was completed in a face-to-face interview.Survey Instrument
Following Lancsar and Louviere [29], a set of treatment attributes
associated with the use of BAs in patients with RA was selected to
populate the choice questions in the survey instrument. The list
of RA treatment attributes was defined after reviewing published
literature in PubMed, Lilacs, and Cochrane databases by using as
search terms ‘‘Arthritis, Rheumatoid,’’ ‘‘anti-TNF,’’ ‘‘abatacept,’’
‘‘adalimumab,’’ ‘‘anakinra,’’ ‘‘infliximab,’’ ‘‘rituximab,’’ and ‘‘eta-
nercept.’’ Also, information from randomized controlled clinical
trials, clinical trials, and systematic reviews was considered inselecting both treatment attributes and defining the attributes’
plausible ranges (attribute levels). In addition, in-depth semi-
structured interviews were conducted with 9 rheumatologists
with extensive experience with BA treatment in patients with RA,
and four focus-group interviews (two in each study site) were
conducted with 27 patients with RA (8 men and 19 women) with
a median age of 60 years (range of 24–75 years).
As a result of this process, the projected sample size, and the
analysis plan for the data collected [30], a final set of seven
attributes and their associated levels was selected. These attri-
butes were 1) clinical efficacy as determined by changes in the
Patient Global Assessment scale, 2) mode of administration,
3) frequency of administration, 4) localized adverse events,
5) generalized adverse events, 6) serious infections, and 7) cost
of treatment. Table 1 summarizes the list of attributes and
corresponding levels under each attribute.Experimental Design
The DCE data-generation process relies on the use of an experi-
mental design to construct attribute combinations that make up
hypothetical treatment profiles and populate the choice ques-
tions in the survey. An experimental design identifies an efficient
combination of profiles that can ensure enough statistical infor-
mation about respondents’ preferences for treatment attributes
using a limited number of choice questions.
An unlabeled, blocked fractional-factorial design optimizing
D-efficiency was generated with 32 choice questions that
Table 2 – Sociodemographic characteristics of
patients with rheumatoid arthritis (n ¼ 240).
Characteristics
Age (y), mean  SD 56.2  13.5
Female sex (%) 87.1
Educational attainment (%)
Incomplete primary school 8.4
Complete primary school 29.7
Incomplete secondary school 15
Complete secondary school 22.6
Tertiary or higher education 24.3
Occupation (%)
Students 2.1
Housewives 31.2
Employed 35.4
Unemployed 11
Retired 20.2
Health coverage (%)
Social security 44.7
Private health insurance plan 34.2
Uninsured 21.1
Family monthly income (%)
oAR $949 18.6
Between AR $949 and AR $1649 18.2
Between AR $1650 and AR $2540 24.1
Between AR $2541 and AR $4041 21.6
AR $4041 17.3
 Exchange rate as of December 2011 was US $1 ¼ 4.28
Argentine pesos.
Table 3 – Disease-related characteristics of the
study sample (n ¼ 240).
Characteristics
Duration of disease, median (range) 9 (0–44)
DMARDs therapy
Methotrexate (%) 84.5
Azathioprine (%) 0
Hydroxicloroquine (%) 18
Leflunomide (%) 24.7
Sulfasalazine (%) 2.1
Gold (%) 0
Penicillamine (%) 0
Hospitalized in the last year (%) 5
Number of tender joints, median (range) 1 (0–22)
Number of swollen joints, mean (range) 1 (0–20)
Patient global assessment, median (IQR) 3.1 (1.8–6)
Physician global assessment, median (IQR) 2 (1–5)
CDAI median (IQR) 7.5 (3.5–16)
CDAI o 2.8 21.1
CDAI (2.8–o10), low disease activity (%) 37
CDAI (10–22) moderate disease activity (%) 24.5
CDAI (422) high disease activity (%) 17.4
HAQ score, median (IQR) 0.5
(0–1.225)
HAQ scores (0–1), mild to moderate difficulty (%) 69.4
HAQ DI scores (1–2), moderate to severe
difficulty (%)
26
HAQ DI scores (2–3), severe disability (%) 4.6
EQ-5D questionnaire (%)
Patients with RA with any limitation in mobility 41.9
Patients with RA with any difficulty with
self-care activities
24.5
Patients with RA with any difficulty to perform
usual activities
42.3
Patients with RA with pain or discomfort 58
Patients with RA with anxiety or depression 32.1
Visual analog scale feeling thermometer,
mean  SD
70.2  20.6
CDAI, clinical disease activity index; DI, Disability Index; DMARDs,
disease-modifying antirheumatic drugs; EQ-5D, EuroQol five-
dimensional; HAQ, Health Assessment Questionnaire; IQR, inter-
quartile range; RA, rheumatoid arthritis.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 8 5 – 3 9 3388included two hypothetical RA treatments in each [31]. The final
number of combinations used was largely determined by the
number of attributes and attribute levels included in the study as
well as the number of interaction terms to be tested. Figure 1
presents an example of a choice question produced with the
experimental design in the survey.
We used SPSS 11.0 package to generate the fractional factorial
design, resulting in 32 hypothetical alternatives from 1944 pos-
sible combinations in which levels of attributes varied indepen-
dently. Profiles were randomly generated. Our main decision
rules were to maximize orthogonality, to have a minimum
number of treatment profiles for each attribute level, and a
reasonable level of balance. Details about the final DCE choice
sets and the balance between each attribute level can be seen in
Appendix 1 in Supplement Materials found at http://dx.doi.org/
10.1016/j.jval.2012.11.007. The 32 choice sets were randomly
allocated in three blocks (two of 11 choice sets and one of 10).
Two versions of each block in which the same profiles were
presented in a reverse order were administered to control for
potential sequence effects. This led us to six different versions of
the survey questionnaire. Alternatives were presented in a
generic form (treatment A or B). An unlabeled design was chosen
on the basis of the fact that eligible patients were not familiar
with BAs, thus enabling them to focus on selected attributes.
Two extra choice sets were added to each block to check
internal consistency and rationality. Respondents were asked to
select which treatment profile they would prefer for the manage-
ment of their RA symptoms in each of the 12 (or 13) choice
questions. This number of questions has been widely used before
[29] and also shown to be feasible and understandable in our pilot
study with 10 patients with RA with low educational attainment.
A forced-choice design was used.
Respondents were given a thorough description about the DCE
survey. Attributes and levels were carefully explained torespondents by using pictures specifically designed for this
purpose in a friendly graphic format.
Model Estimation
A sample size of 240 subjects was used to estimate the patient-
preference model. A probit model was used to analyze the choice
data collected in the study [31]. Data were coded according to
conventional guidelines [31], using a categorical representation of
each attribute level in the experimental design. The use of
categorical variables eliminates the need to impose a functional
form on respondents’ preferences, and allows for nonlinear
effects across the attribute levels. The analysis was carried out
with STATA 9.0.Results
Between September 2009 and April 2010, 396 patients were
eligible to participate and 240 patients were included after
Table 4 – Results from the discrete-choice experiment (probit model).
Treatment attributes and levels Coefficient 95% Confidence intervals P
Lower Upper
Efficacy (n PGA)
30 mm1 .0452443 .1438011 .0533126 0.368
20 mm1 .4133501 .5041043 .32259 o0.001
Mode of administration
Subcutaneous2 .0027681 .0904586 .0959948 0.954
Intravenous2 .4115388 .5039187 .3191589 o0.001
Frequency of administration
Every month3 .453254 .5621269 .3443812 o0.001
Every week3 .1245207 .2282101 .0208313 0.019
Every day3 .6155396 .7135149 .5175643 o0.001
Local adverse events
15%4 .2900352 .3913451 .1887253 o0.001
40%4 .3950064 .4841144 .3058985 o0.001
Generalized adverse events
10%5 .305863 .4043812 .2073448 o0.001
30%5 .666305 .7605984 .5720116 o0.001
Serious infections—5%6 .2972624 .3744642 .2200605 o0.001
Cost
$500 per month7 .1305259 .0468865 .2141654 0.002
$1500 per month7 .6680879 .7656879 .5704879 o0.001
Constant term 1.257734 1.117825 1.397642 o0.001
Number of observations/respondents 5092/240
Wald w2 729.00
Prob 4 w2 o0.001
Pseudo R 0.1410
Note. Level of reference: 1, n 40 mm; 2, oral; 3, every 10 mo; 4, no risk of local adverse events; 5, no risk of generalized adverse events; 6, 1%; 7,
no costs. Consider that every level of the attribute is compared with the best possible level of the corresponding attribute.
PGA, patient global assessment of disease activity.
 The parameter estimate for the dichotomous variable addresses any difference in the probability that a profile is picked if shown on the left
(as opposed to the right) side of a choice question. This difference in the probability of being selected captured by this parameter goes beyond
what is already explained by the treatment attributes.
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eligible participants was 56.26  13.16 years, 86% were women,
and the median duration of RA was 9 years ( interquartile range
5–17). Median Health Assessment Questionnaire value was 0.5
(interquartile range 0–1.225) and median clinical disease activity
index was 7.5 (interquartile range 3.5–16) (see Table 2). Other
sociodemographic characteristics of the included subjects are
shown in Table 2, and disease-related characteristics are shown
in Table 3.
In the DCE, 98.7% of the sample correctly preferred a treat-
ment that was better in all attributes than the alternative. This
suggests that respondents were paying attention to the choice
task. Regarding internal consistency, the overall intrarater per-
centage of agreement and kappa statistics were 76.57% and 0.53
(95% confidence interval [CI] 0.42–0.63), respectively.
The parameter estimates obtained with the model represent
preference weights for each one of the attribute levels in the
study. Main results of the probit model are presented in Table 4.
The model baseline (reference level used for all attributes
expressed in the constant) is based on an oral agent taken every
10 months that has no cost to patients with RA, the highest level
of efficacy, no risk of local or generalized reactions, and a 1% risk
of serious infection. Positive estimates for attribute levels repre-
sent levels that are relatively preferred over the baseline values
included in the constant of the model (For the probit model, we
differenced the utility from the pair of alternatives in each choice
question during the setup of the data. This is different from how
traditional multinomial logit models consider the difference inutility from alternatives, which is done implicitly in the like-
lihood function [32]).Because the choice variable is conditioned
on the utility difference directly, it is possible to identify one
constant in the model specification. In this case, we created a
dichotomous variable set to be equal to 1 for all profiles that were
presented on the left side of each choice question, and 0
otherwise. Given that we always subtract the utility of treatment
profiles shown on the right side of a choice question from the
utility of treatment profiles shown on the left side of a choice
question, the parameter estimate for the dichotomous variable
addresses any difference in the probability that a profile is picked
if shown on the left (as opposed to the right) side of a choice
question. This difference in the probability of being selected
captured by this parameter goes beyond what is already
explained by the treatment attributes.
Negative estimates represent levels that are relatively less
preferred than the baseline values in the constant. The attribute
levels with a statistically significant influence in patient choice
were those with coefficients (and their CIs) different from 0, and
thus with a P value of less than 0.05.
In general, preferences for the levels under each treatment
attribute are consistent with the a priori expectation that levels
with greater efficacy, lower toxicities, or adverse effects have
higher preference weights (hence are more preferred) than levels
representing lower efficacy, greater likelihood of toxicity, or
adverse effects of treatment.
Coefficients for the following treatment attributes and levels
were statistically significant and independently less preferred
Table 5 – Attributes’ mean and confidence intervals (CIs) to evaluate the importance of attribute levels.
Attribute Mean 95% CI
Lower bound Upper bound
Cost 0.8058 0.6884 0.9245
General adverse events 0.6654 0.5696 0.7573
Frequency 0.6145 0.5164 0.7124
Efficacy 0.4174 0.3253 0.5094
Mode 0.4129 0.3053 0.5208
Local adverse events 0.3981 0.3068 0.4875
Serious infection 0.2938 0.2190 0.3701
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assessment improvement [PGA] of 20 mm); intravenous mode
of administration; a monthly, weekly, and daily frequency of
administration; a 15% and 40% risk of local adverse events; a 10%
and 30% risk of generalized adverse events; a 5% risk of serious
infections; and an out-of-pocket monthly costs of AR $500 and AR
$1500 (equivalent to US $128 and $385 at the mean exchange rate
of 2010). Significant parameter estimates indicated that these
attributes were important factors affecting patients’ choice of
treatment. The constant term was also statistically significant
indicating that other unobserved attributes were also likely to
influence treatment preferences.
Almost all the coefficients for attribute levels were negative
except cost AR $500, which was positive. A negative sign for the
attribute n PGA of 20 mm indicated that utility decreases with
lower efficacy of a treatment for RA. Similarly, the negative signs
of coefficient for the adverse events indicated that the higher the
risk of experiencing adverse events (local, generalized adverse
events, and infections), the less desirability of the profile.
To adjust for potential confounding variables, we adjusted the
parameter estimates in the models for the following potential
confounders: age category, gender, educational level, time from
disease diagnosis, site of recruitment, and clinical disease activ-
ity index strata. The adjusted model had similar results to the
unadjusted model, suggesting that there was no significant
confounding effect between these patient characteristics and
patient preferences.
To evaluate whether preferences differed by some sample
subgroup, we generated three dichotomous variables for age
(older or younger than 55 years), site (public vs. private hospital),
and respondents’ self-reported income (three lower quintiles, up
to AR $2540 vs. two top quintiles AR $ 42540). We tested whether
these dichotomous variables had interactions with each one of
the attribute levels in the study. By using the parameter estimates
for these interaction terms, we tested the statistical significance
differences in the preference weights for attribute levels across
these subgroups.
The interaction term between site and intravenous mode of
administration showed a borderline statistical significance. Inter-
estingly, age was shown to interact significantly with preferences
regarding efficacy levels. Interaction between age older or
younger than 55 years was significantly different from zero
(P o 0.01). Younger patients valued more negatively each
decrease in efficacy from the comparator of n PGA of 40 mm,
while older patients were more tolerant to smaller differences in
BA effects (especially to n; PGA of 30 mm, which had almost no
difference to n PGA of 40 mm with a near-zero coefficient). In the
case of income interactions, we found that income interacts
significantly with preferences for treatment cost. While less
affluent respondents saw no difference between no cost and
paying AR $500 for RA treatments, more affluent respondents
preferred paying AR $500 over receiving their RA treatment at nocost. We present the subgroup analyses showing these interac-
tions in Appendix 2 in Supplemental Materials found at http://dx.
doi.org/2010.1016/j.jval.2012.11.007.
To evaluate the relative importance of the attributes of RA
treatments considered in the study, a comparison of the relative
magnitude of coefficients was performed. The relative impor-
tance of an attribute refers to the difference between the
preference weight of the most favored level and that of the least
favored level in an attribute. Thus, the relative importance of
attributes depends on the range covered by the levels in an
attribute. Table 5 presents the mean (and 95% CI) relative
importance of each attribute (To estimate the relative importance
of each attribute and its 95% CI, we used the Krinsky-Robb
method. A 10,000-value vector was generated by using the model
coefficients and their variance-covariance structure to simulate
differences in the extreme values for the attribute levels under
each attribute.)
The order of the attributes in terms of importance (from most
important to least important) was cost, general adverse events,
frequency of administration, efficacy, mode of administration,
local adverse events, and serious infection.
To evaluate the unusual results observed regarding the inter-
mediate treatment cost (AR $500), we tested the hypothesis that
respondents assumed a time payment for medications and
evaluated the relationship of respondents’ self-reported income
and treatment costs. We found that more affluent patients
preferred paying AR $500 to AR $0 for their medicines. However,
less affluent patients were indifferent between no cost and AR
$500, suggesting that even these patients are considering the
negative impacts of the bureaucratic hassle associated with
receiving RA treatments at no cost (see Appendix 2 Table 2 and
Appendix 3).
To calculate willingness to pay (WTP) for RA treatment
features, we used the portion of the marginal utility of out-of-
pocket expenses that does not change with respondents’ income,
the estimated disutility for changes in out-of-pocket costs
between AR $500 and AR $1500. We scaled utility changes
between RA treatments’ attribute levels by the estimated slope
for the marginal utility of out-of-pocket costs between AR $500
and AR $1500. For example, changing a patient from a treatment
profile with more severe adverse effects and the greatest level of
treatment benefit to the most preferred treatment profile (reduc-
tion of 40 mm in the PGA score, and requires oral administration
of the treatment every 10 months; with no risk of local adverse
effects, no risk of generalized adverse effects, a treatment-related
risk of serious infection of 1%, and no cost) has a mean WTP of
AR $1439 (95% CI 1168–1749). Interested readers are referred to
Appendix 4 in Supplemental Materials found at http://dx.doi.org/
2010.1016/j.jval.2012.11.007, where we present the WTP results of
selected profiles (of high and low effectiveness, and high and low
adverse events) as well as the results of all possible profiles’
combinations.
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Understanding the preferences of patients and health profes-
sionals is essential for health policy and planning. RA preferences
have been previously addressed by using instruments such as the
McMaster Toronto Arthritis Patient Preference Disability Ques-
tionnaire [33], the Problem Elicitation Technique [34], and the
Arthritis Impact Measurement Scale 2 [5] questionnaire. The
McMaster Toronto Arthritis Patient Preference Disability Ques-
tionnaire and the Problem Elicitation Technique mainly asked
patients with RA to indicate which functional ability they would
most like to see improved [34,35], while the Arthritis Impact
Measurement Scale 2 focused on those health dimension areas
that patients with RA wanted to improve. In these instruments,
pain was identified as the main attribute patients with RA
preferred to address in a large community-based sample of
1024 patients with RA [36]. The main constrain related to the
use of the McMaster Toronto Arthritis Patient Preference Dis-
ability Questionnaire, the Problem Elicitation Technique, and the
Arthritis Impact Measurement Scale 2 was that they focused
mainly on health outcomes preferences and that they do not
elicit preferences in a more realistic environment of everyday
choices.
The results from our study showcase the feasibility of using
DCEs to elicit patients’ preferences for RA treatments and BA
therapies. Although DCEs have been used for some decades now
in many areas, they have been incorporated into health rather
recently, and mainly in high-income countries. Only very recently
we can find some examples being applied in low- and middle-
income countries to consider a range of several policy concerns
[37].
The present study is to our knowledge the first one to use a
DCE design in the health care field in the region, and to
specifically evaluate RA patient preferences regarding treatment
with BAs.
The discrete choice exercise conducted among a sample of
Argentinean patients with RA adhered to all the necessary steps
that safeguard the internal validity of this type of design [11,38].
The main output of this study is a regression equation that allows
us to quantitatively evaluate the relative weight and importance
attributes evaluated have for patients with RA in order to make a
choice about what they would prefer. In addition, this type of
study aids to quantify and evaluate the magnitude and impor-
tance of trade-offs patients make among the different attributes.
Results show that attributes can be ranked in the following
order on the basis of their relative importance for patients (from
most important to least important): cost, general adverse events,
frequency of administration, efficacy, mode of administration,
local adverse events, and serious infection.
Compared with the best levels of each attribute, the following
levels showed statistically significant coefficients: efficacy (n PGA
of 20 mm); intravenous mode of administration; a monthly,
weekly, and daily frequency of administration; a 15% and 40%
risk of local adverse effects; a 10% and 30% risk of generalized
adverse events; a 5% risk of serious infections; and an out-of-
pocket monthly cost of AR $500 and AR $1500. This indicated that
these attributes were important factors affecting patients’ choice
of treatment.
In the main analysis, we found that the coefficient for the
attribute level cost AR $0 was significantly less preferred than the
AR $500 option, but not AR $1500. This implies that patients
would prefer to pay AR $500 for their RA treatments to receiving
the treatment at no cost. Although this appears to be a counter-
intuitive result, during the pilot testing of the survey instrument,
patients stated that receiving RA treatments at no cost required a
lot of time-consuming bureaucratic steps and get an officialdisability certificate. (This point was first risen during the focus
groups conducted at the initial qualitative phase of the study.)
The ‘‘bureaucratic hassle’’ associated with receiving RA treat-
ments at no cost represents a procedural barrier that increases
the real cost of treatment even when patients do not need to use
money to pay for their drugs. In essence, patients who pay
nothing for their medications are required to pay a ‘‘time fee’’
to resolve all the necessary bureaucratic steps before they can
receive their medicine.
Because of the potential confounding between monetary and
nonmonetary costs in the elicitation of preferences for AR $0, we
lack a reliable estimate of the marginal utility of changes in
treatment cost between AR $0 and AR 500. The study design did
not explicitly include time costs or information on the level of
bureaucratic hassle that could be expected with the acquisition
of a treatment for AR $0. Thus, it was not possible to test for the
potential association between preferences for nonmonetary cost
and other potential costs assumed by respondents. Instead, only
the marginal utility induced by changes in treatment cost
between AR $500 and AR $1500 was used for the calculation of
WTP. The use of the marginal utility of out-of-pocket costs
between AR $500 and AR $1500 for all WTP calculations requires
assuming that marginal utility of income is constant for the
changes considered in the study. This is the case because
preferences for changes in out-of-pocket costs can also be
interpreted as changes for different income levels, as purchasing
a good for a nonzero price results in having less income available
for other purchases.
Another finding was that as compared with the baseline
frequency of treatment (treatment every 10 months), the weekly
frequency was preferred to daily or monthly frequencies. This is
not an unusual finding, because in some cases subjects prefer
more frequent (and tractable) treatment schedules to avoid
having to remember or plan an irregular (less tractable) treat-
ment schedule. Once a week frequency appears to be enough to
reduce any inconvenience associated with receiving the therapy,
but not infrequently enough to allow for a stable routine that
help patients adhere to treatment.
Although we did not find a single study that had the same
research question we addressed (i.e., what are patient prefer-
ences and trade-offs between the different attributes of newer
biologic drugs for RA), DCE and other studies have been per-
formed in patients with RA [15,39]. In the DCE study, authors
reported that preferences were significantly influenced by aver-
sion to risk toxicity, though they did not report the model results
and their coefficients. Although generalized adverse events were
found to be important in our study, they were very similar in
importance to the frequency of administration, and cost was the
more important attribute.
Some limitations of our study are worth noting. These include
the following: 1) There was moderate consistency within patients
regarding the response to an equal choice set at the beginning
and the end of the DCE exercise (the overall intrarater percentage
of agreement and kappa statistics were 76.57% and 0.53 [95% CI
0.42–0.63]). This is not uncommon in DCE studies, and can be
explained as a learning or order effect [31]. Previous studies
[40–43] found that learning throughout the exercise and fatigue
worked in opposite directions to affect subjects’ stated prefer-
ences. Even though patients are explained the attributes and
attribute levels before starting the DCE questions in the survey,
respondents improve their understanding of the choice tasks as
they answer the choice questions. Thus, respondents commonly
fail to consistently answer choice questions presented at the
beginning and at the end of the DCE section. After comparing the
demographics of those who failed the consistency test compared
with those who did not, there were no differences regarding sex,
age, educational attainment, years since RA diagnosis, disease
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 8 5 – 3 9 3392activity, or physical function. Also, order effects were controlled
for in the study design as the order of each block of choice sets
was different in different subgroups (set reversion). 2) Although
the internal validity of the study was high, this was a study of
patients with RA representative of public and social security/
private sector in Argentina, and may not be necessarily general-
izable to other national systems. We believe that results are
probably more representative of patients’ preferences in Argen-
tina and possibly Latin America. 3) By design, this study included
patients with mainly mild to moderate disease activity, as we
wanted them to be naive related to personal experiences with BA.
But, in real life, candidates for BAs have somewhat more severe
symptoms. To address the question of whether the severity of
symptoms would affect patient preferences in any significant
way, we adjusted the model estimates for disease activity as a
covariate and found that symptom severity did not influence
patients’ preferences. 4) Preferences for treatment cost appear to
be influenced by respondents’ endogenous interpretation of the
no-cost level. Although we have already identified evidence
suggesting that respondents recoded the levels in the cost
attribute, more in-depth work could (and should) be done to
address this issue in a more conclusive fashion.
To conclude, the present study is to our knowledge the first
one to use a DCE design in the health care field in the Latin
American region, and to specifically evaluate RA patient prefer-
ences regarding treatment choices with BAs.Acknowledgments
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